Cargando…
HIV Dementia with a Decreased Cardiac (123)I-metaiodobenzylguanidine Uptake Masquerading as Dementia with Lewy Bodies
Cardiac (123)I-metaiodobenzylguanidine (MIBG) scintigraphy is a promising biomarker for dementia with Lewy bodies (DLB). However, we experienced a patient with cognitive decline, parkinsonism, and a decreased MIBG uptake who turned out to have HIV dementia. Normal dopamine transporter single-photon...
Autores principales: | Kurihara, Masanori, Sasaki, Takuya, Ishiura, Hiroyuki, Tsuji, Shoji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232034/ https://www.ncbi.nlm.nih.gov/pubmed/29780124 http://dx.doi.org/10.2169/internalmedicine.0876-18 |
Ejemplares similares
-
Uptake Index of (123)I-metaiodobenzylguanidine Myocardial Scintigraphy for Diagnosing Lewy Body Disease
por: Kamiya, Yoshito, et al.
Publicado: (2017) -
(123)I-Metaiodobenzylguanidine Myocardial Scintigraphy in Lewy Body-Related Disorders: A Literature Review
por: Chung, Eun Joo, et al.
Publicado: (2015) -
Autopsy Validation of the Diagnostic Accuracy of (123)I-Metaiodobenzylguanidine Myocardial Scintigraphy for Lewy Body Disease
por: Matsubara, Tomoyasu, et al.
Publicado: (2022) -
Development of an (123)I-metaiodobenzylguanidine Myocardial Three-Dimensional Quantification Method for the Diagnosis of Lewy Body Disease
por: Kamiya, Yoshito, et al.
Publicado: (2018) -
Accuracy and cutoff values of delayed heart to mediastinum ratio with (123)I-metaiodobenzylguanidine cardiac scintigraphy for Lewy body disease diagnoses
por: Lamotte, Guillaume, et al.
Publicado: (2015)